PMID- 31037211
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 2040-6223 (Print)
IS  - 2040-6231 (Electronic)
IS  - 2040-6223 (Linking)
VI  - 10
DP  - 2019
TI  - Nonwalking response to fampridine in patients with multiple sclerosis in a 
      real-world setting.
PG  - 2040622319835136
LID - 10.1177/2040622319835136 [doi]
LID - 2040622319835136
AB  - OBJECTIVES: Mobility impairments constitute a long-term burden in patients with 
      multiple sclerosis (MS). Currently there is evidence that the drug fampridine may 
      improve nonwalking symptoms in MS patients. The main objective of this study is 
      to analyze whether participants showing a beneficial walking response to 
      fampridine, also show a positive response in nonwalking assessments in a 
      real-world clinical setting. METHODS: Subjects enrolled were part of a study 
      analyzing gait parameters, for which response to treatment with fampridine was 
      monitored after a period of 2 weeks. Neurologists then decided whether patients 
      were responders to fampridine (RF) according to their global impression of 
      patients' gait improvement. As nonwalking outcomes, we included the nine-hole peg 
      test (9-HPT), the EuroQoL five dimensions questionnaire (EQ-5D) for quality of 
      life, The Wurzburger Fatigue Inventory for MS (WEIMuS), the Center for 
      Epidemiologic Studies depression scale (CES-D), and the Paced Auditory Serial 
      Addition Test (PASAT). Minimal clinically important difference (MCID) was 
      evaluated for each test. RESULTS: A total of 189 participants were included: 122 
      were women (64.55%), with a mean age of 53.55 (+/-10.83). RFs showed significant 
      improvement in all of the nonwalking outcomes (p < 0.05), except for a 
      nonsignificant improvement in nondominant upper limb function and PASAT; the 
      largest score improvement was seen in the physical and cognitive sections of the 
      WEIMuS (25.69% and 29.81%, respectively, p < 0.001). CONCLUSION: We provide 
      evidence that physician's global judgement of walking improvement is a reliable 
      measure for determining response to fampridine in nonwalking parameters, with 
      fatigue showing the greatest score improvement after 2 weeks.
FAU - Rodriguez-Leal, Francisco Alejandro
AU  - Rodriguez-Leal FA
AD  - Center of Clinical Neuroscience, University Hospital, Carl Gustav Carus, TU 
      Dresden, Germany.
FAU - Haase, Rocco
AU  - Haase R
AD  - Center of Clinical Neuroscience, University Hospital, Carl Gustav Carus, TU 
      Dresden, Germany.
FAU - Akgun, Katja
AU  - Akgun K
AD  - Center of Clinical Neuroscience, University Hospital, Carl Gustav Carus, TU 
      Dresden, Germany.
FAU - Eisele, Judith
AU  - Eisele J
AD  - Center of Clinical Neuroscience, University Hospital, Carl Gustav Carus, TU 
      Dresden, Germany.
FAU - Proschmann, Undine
AU  - Proschmann U
AD  - Center of Clinical Neuroscience, University Hospital, Carl Gustav Carus, TU 
      Dresden, Germany.
FAU - Schultheiss, Thorsten
AU  - Schultheiss T
AD  - Center of Clinical Neuroscience, University Hospital, Carl Gustav Carus, TU 
      Dresden, Germany.
FAU - Kern, Raimar
AU  - Kern R
AD  - Center of Clinical Neuroscience, University Hospital, Carl Gustav Carus, TU 
      Dresden, Germany.
FAU - Ziemssen, Tjalf
AU  - Ziemssen T
AD  - Center of Clinical Neuroscience, Department of Neurology, University Hospital 
      Carl Gustav Carus, Fetscherstr. 74, Dresden, 01307, Germany.
LA  - eng
PT  - Journal Article
DEP - 20190419
PL  - United States
TA  - Ther Adv Chronic Dis
JT  - Therapeutic advances in chronic disease
JID - 101532140
PMC - PMC6475844
OTO - NOTNLM
OT  - 4-aminopyridine
OT  - cognition
OT  - depressive symptoms
OT  - fampridine
OT  - fatigue
OT  - multiple sclerosis
OT  - quality of life
OT  - upper extremity
COIS- Conflict of interest statement: Katja Akgun has received personal compensation 
      for oral presentation from Novartis, Bayer, and Biogen Idec. Undine Proschmann 
      has received travel support from Novartis and Biogen Idec. Tjalf Ziemssen has 
      received personal compensation for consultation and speaking fee as well as grant 
      support by Biogen, Bayer, Celgene, Merck, Novartis, Sanofi, Teva, and Roche and 
      is section editor for BMC Neurology. Francisco Alejandro Rodriguez-Leal, Rocco 
      Haase, Judith Christina Eisele, Thorsten Schultheiss, and Raimar Kern have no 
      conflicting interests to declare.
EDAT- 2019/05/01 06:00
MHDA- 2019/05/01 06:01
PMCR- 2019/04/19
CRDT- 2019/05/01 06:00
PHST- 2018/10/30 00:00 [received]
PHST- 2019/02/06 00:00 [accepted]
PHST- 2019/05/01 06:00 [entrez]
PHST- 2019/05/01 06:00 [pubmed]
PHST- 2019/05/01 06:01 [medline]
PHST- 2019/04/19 00:00 [pmc-release]
AID - 10.1177_2040622319835136 [pii]
AID - 10.1177/2040622319835136 [doi]
PST - epublish
SO  - Ther Adv Chronic Dis. 2019 Apr 19;10:2040622319835136. doi: 
      10.1177/2040622319835136. eCollection 2019.